CCM
WX

Causeway Capital Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Causeway Capital Management’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-65,400
Closed -$2.83M – 88
2015
Q3 		$2.83M Buy
65,400
+3,500
+6% +$148K 0.06% 68
2015
Q2 		$2.57M Sell
61,900
-43,700
-41% -$1.84M 0.06% 63
2015
Q1 		$4.09M Sell
105,600
-75,100
-42% -$2.89M 0.11% 64
2014
Q4 		$6.08M Hold
180,700
– – 0.18% 57
2014
Q3 		$6.33M Buy
180,700
+54,700
+43% +$1.87M 0.22% 58
2014
Q2 		$4.14M Sell
126,000
-31,500
-20% -$1.08M 0.17% 57
2014
Q1 		$4.94M Buy
157,500
+19,100
+14% +$701K 0.22% 54
2013
Q4 		$5.31M Buy
138,400
+31,800
+30% +$1M 0.3% 51
2013
Q3 		$2.92M Buy
+106,600
New +$2.53M 0.24% 48

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Causeway Capital Management's WX Position: Q4 2015 in Review

Causeway Capital Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 65,400 shares — an estimated $2.83M sold.

Causeway Capital Management first reported a position in WX in Q3 2013 and held it in 9 quarters. The position peaked at $6.33M in Q3 2014. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Causeway Capital Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Causeway Capital Management sold 65,400 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $2.83M.
  • Causeway Capital Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 9 quarters.
  • Causeway Capital Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $6.33M in Q3 2014.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Causeway Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.